Market
How many live births will be achieved using GametoGen's iPSC technology by end of 2025?
2
Resolution / Starting Odds
Less than 50 • 25%
50 to 199 • 25%
200 to 499 • 25%
500 or more • 25%
Official reports from GametoGen or industry publications
Story
GametoGen Achieves First Live Birth Using iPSC Technology in IVF, Reducing Hormone Injections by 80% and Treatment to Three Days
Dec 16, 2024, 04:09 PM
GametoGen, a next-generation IVF startup, has announced the first successful live birth using its innovative technology, which utilizes induced pluripotent stem cell (iPSC)-derived ovarian cells. This groundbreaking achievement marks a significant milestone in reproductive technology, as the company claims it is the first human birth resulting from iPSC technology. The new method reportedly replaces 80% of the hormone injections typically required in traditional IVF and shortens treatment cycles to just three days. The announcement has garnered attention for its potential to revolutionize access to IVF and improve outcomes for families seeking fertility assistance.
View original story
Similar markets
11 to 20 • 25%
More than 20 • 25%
Less than 5 • 25%
5 to 10 • 25%
More than 20 • 25%
0-5 • 25%
6-10 • 25%
11-20 • 25%
Q4 2025 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
6-10 • 25%
11-15 • 25%
More than 15 • 25%
0-5 • 25%
6-10 transplants • 25%
More than 20 transplants • 25%
11-20 transplants • 25%
0-5 transplants • 25%
Other • 25%
Regenerative Medicine • 25%
Anti-Aging Treatments • 25%
Cancer Therapy • 25%
10 or more • 25%
1-3 • 25%
4-6 • 25%
7-9 • 25%
No Improvement • 25%
Harmful Effects • 25%
Significant Improvement • 25%
Moderate Improvement • 25%
10 to 20 • 25%
More than 50 • 25%
Less than 10 • 25%
21 to 50 • 25%
31-40 labs • 25%
41-50 labs • 25%
20-30 labs • 25%
More than 50 labs • 25%
More than 100,000 • 25%
50,001 to 100,000 • 25%
10,000 to 50,000 • 25%
Less than 10,000 • 25%
